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Reply
We thank Dr. Boersma for his comments on our work (1) and we
appreciate the opportunity to respond. We agree that the many
therapeutic options now available for acute coronary syndrome
(ACS) patients create a need to implement these options ratio-
nally. It was because of this need that we used data from
randomized clinical trials in a formal decision analysis to provide
estimates of the probability of outcomes with each of the thera-
peutic strategies modeled.
Concern is raised about three specific estimates used and
their effect on the results of the principal analysis. First,
Dr. Boersma comments on the value of zero for the lower limit
of the confidence interval (CI) for death in TARGET (Do
Tirofiban and ReoPro Give Similar Efficacy Outcomes?) trial
ACS (2). This was a typographical error; as indicated in Table
3, the range that was used was 1.0 to 2.5. Thus, our sensitivity
analysis ranges from being neutral to detrimental for the
upstream strategy. Second, we did not use the differing rates of
major bleed reported in the TARGET trial for our baseline
analysis, because these were not statistically significantly differ-
ent (p  0.43); thus, there was insufficient evidence of a true
difference in bleeding. Nonetheless, had we used the TARGET
trial rates, the number of bleeds saved with abciximab would
have increased from 500 to 660 per 100,000 patients treated,
and the cost per year of life saved with the upstream strategy
would have changed from $18,000 to $18,350, which is still
economically favorable. Third, the principal estimate for the
effect of small-molecule glycoprotein (GP) IIb/IIIa inhibitors
versus placebo during medical management was obtained from
a meta-analysis of relevant randomized clinical trials (3). The
range we tested in sensitivity analysis encompasses the 95% CI
from that same meta-analysis, but it was also widened to explore
the effect of utilizing other relative risks (RRs) cited in the
literature, as listed in our Table 1 (1). However, because we
agree that post hoc analyses may be biased, these other
estimates were not used for our principal analysis; thus, they do
not affect the presented principal results (4,5). In all of these
cases, regardless of the ranges that are used, it is the principal
estimate that is the basis of the results, and thus differing ranges
cannot bias the main result of the study.
We did not report a probabilistic sensitivity analysis—assessed
by second-order Monte Carlo simulation. We cannot rule out that
had we performed such an analysis, the resulting CIs might have
widened. But readers should not overinterpret the possibility of
such wide CIs. When the point estimate ($18,000) is (substan-
tially) less than our willingness to pay, wide CIs may suggest that
we cannot be confident that 2 strategies differ in their value for the
cost, but they do not support an interpretation that upstream use
is bad value compared to selective use.
We agree that decision analysis techniques occasionally may be
mistrusted and misunderstood. We believe that the presentation of
our data was transparent in its choices and limitations. A clinical
trial addressing the question of upstream versus selective use of GP
IIb/IIIa inhibitors is needed. In the absence of a clinical trial,
though, a decision analysis provides valuable insight. In this regard,
we believe that the importance of decision models is their ability to
oblige clinicians and researchers alike to formalize how each piece
of evidence or assumption at key decision points impacts our belief
of what constitutes an optimal management strategy.
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